Sanofi says profits hit by patent expiry, vaccine problems

French pharmaceutical group Sanofi reported a slump in profits for the third quarter of the year on Wednesday owing to the lagging effects of the ending of exclusive patent rights.

The group, downgrading slightly the outlook for full-year results, said that fell, and that an additional factor weighing on performance was production problems for vaccines in the United States.

Net profit for the quarter fell by 21.2 percent to 1.2 billion euros ($1.65 billion) and sales by 6.7 percent to 8.4 billion euros.

Sanofi said that even though it expected to achieve renewed growth in the fourth quarter, the vaccine problem in the third quarter meant that it was lowering its outlook for to the lower end of its previous guidance.

This indicated a fall of about 10.0 percent in net profit.

Managing director Chris Viehbacher said that the effects of losing exclusive rights to some patents had ended in August, and that consequently sales had begun to rise in September.

add to favorites email to friend print save as pdf

Related Stories

Sanofi earnings slashed in first quarter

May 02, 2013

(AP)—French drug maker Sanofi said Thursday its net profit was slashed in the first quarter from a year earlier as falling sales and patent losses on key drugs combined to hammer earnings.

Sanofi warns on '13 profit as Q2 earns slump (Update)

Aug 01, 2013

Competition from generic drugs continued to hammer French pharmaceutical group Sanofi in the second quarter, the company said Thursday, warning that its full-year earnings could be twice as bad as previous guidance.

Dutch high-tech group ASML posts sharp Q1 slump

Apr 17, 2013

The Dutch company ASML, which supplies computer chip-making systems and is a global high-tech bellwether, posted on Wednesday sharp drops in sales and net profit for the first quarter 2013, but said it expected business to ...

Recommended for you

AbbVie hikes forecast, tops Street expectations

Oct 31, 2014

The drugmaker AbbVie surprised Wall Street on Friday with a third-quarter performance that turned out much better than expected and a new 2014 forecast that also extends well beyond what analysts predict.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.